| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5922695 | GILEAD SCIENCES INC | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jul, 2017
(6 years ago) | |
| US6043230 | GILEAD SCIENCES INC | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul, 2017
(6 years ago) | |
| US5977089 | GILEAD SCIENCES INC | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul, 2017
(6 years ago) | |
| US5935946 | GILEAD SCIENCES INC | Nucleotide analog composition and synthesis method |
Jul, 2017
(6 years ago) | |
|
US6043230 (Pediatric) | GILEAD SCIENCES INC | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jan, 2018
(6 years ago) | |
|
US5922695 (Pediatric) | GILEAD SCIENCES INC | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jan, 2018
(6 years ago) | |
|
US5935946 (Pediatric) | GILEAD SCIENCES INC | Nucleotide analog composition and synthesis method |
Jan, 2018
(6 years ago) | |
|
US5977089 (Pediatric) | GILEAD SCIENCES INC | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jan, 2018
(6 years ago) | |
Viread is owned by Gilead Sciences Inc.
Viread contains Tenofovir Disoproxil Fumarate.
Viread has a total of 8 drug patents out of which 8 drug patents have expired.
Expired drug patents of Viread are:
- US5922695
- US6043230
- US5977089
- US5935946
- US6043230*PED
- US5922695*PED
- US5935946*PED
- US5977089*PED
Viread was authorised for market use on 18 January, 2012.
Viread is available in tablet;oral, powder;oral dosage forms.
Viread can be used as treatment of chronic hepatitis b in adults and pediatric patients 12 years of age and older, treatment of hiv infection in combination with one or more additional hiv antiviral agents, treatment of hiv.
The generics of Viread are possible to be released after 25 January, 2018.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-569) | Aug 11, 2011 |
| M(M-128) | Jul 24, 2016 |
| M(M-95) | Oct 01, 2013 |
| Pediatric Exclusivity(PED) | Apr 01, 2014 |
| New Patient Population(NPP) | Aug 16, 2015 |
| Orphan Drug Exclusivity(ODE) | Mar 24, 2017 |
Drugs and Companies using TENOFOVIR DISOPROXIL FUMARATE ingredient
Market Authorisation Date: 18 January, 2012
Treatment: Treatment of chronic hepatitis b in adults and pediatric patients 12 years of age and older; Treatment of hiv infection in combination with one or more additional hiv antiviral agents; Treatment of hi...
Dosage: TABLET;ORAL; POWDER;ORAL
VIREAD family patents
